10:06 AM EDT, 08/18/2025 (MT Newswires) -- Genprex ( GNPX ) said Monday that the US Patent and Trademark Office and the European Patent Office have issued notices of allowance for patents covering the use of Reqorsa gene therapy in combination with immune checkpoint inhibitors.

The patents, which are set to expire in 2037 at the earliest, will cover the use of Reqorsa with PD-L1 antibodies such as Genentech's Tecentriq in the US, and with PD-1 antibodies in Europe, the gene therapy company said.

Genprex ( GNPX ) said it is pursuing additional patents in Europe, Canada, Brazil, China and Israel that, if granted, would support its Acclaim-3 phase 1/2 trial of Reqorsa with Tecentriq as a maintenance therapy for extensive-stage small cell lung cancer.

Shares of Genprex ( GNPX ) were down more than 2% in recent Monday trading.

Price: 0.21, Change: -0.01, Percent Change: -2.37